Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

METTL16 regulates m6A methylation on chronic hepatitis B associated gene HLA-DPB1 involved in liver fibrosis
Haibing Gao, Xiangmei Wang, Huaxi Ma, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 13

Showing 13 citing articles:

The emerging importance role of m6A modification in liver disease
Sheng Wang, Songsen Gao, Wufei Ye, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114669-114669
Open Access | Times Cited: 30
N6-methyladenosine (m6A) RNA modification in fibrosis and collagen-related diseases
Man Tan, Siyi Liu, Lubin Liu
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
m6A RNA methylation drives kidney fibrosis by upregulating β-catenin signaling
Yinyi Long, Dongyan Song, Liuyan Xiao, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 8, pp. 3185-3200
Open Access | Times Cited: 4
Changes in m6A in Steatotic Liver Disease
Belinda J. Petri, Matthew C. Cave, Carolyn M. Klinge
Genes (2023) Vol. 14, Iss. 8, pp. 1653-1653
Open Access | Times Cited: 10
m6A RNA modification pathway: orchestrating fibrotic mechanisms across multiple organs
Xiangfei Huang, Zilu Yu, Juan Tian, et al.
Briefings in Functional Genomics (2025) Vol. 24
Closed Access
RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers
Zhuozheng Shi, Xiankui Cao, Yiming Ma, et al.
Cancer Letters (2025), pp. 217698-217698
Closed Access
Emerging role of m6A modification in fibrotic diseases and its potential therapeutic effect
Wufei Ye, Xiongwen Lv, Songsen Gao, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115873-115873
Closed Access | Times Cited: 8
Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma
Xuan Zha, Zewei Gao, Min Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116966-116966
Open Access | Times Cited: 2
METTL16 in human diseases: What should we do next?
Hui Zhang, Mengqi Yin, Hua Huang, et al.
Open Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
m6A modification in non-coding RNAs: Mechanisms and potential therapeutic implications in fibrosis
Yutong Zhou, Ni Jian, Canhua Jiang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117331-117331
Open Access | Times Cited: 1
N6-methyladenosine in inflammatory diseases: Important actors and regulatory targets
Zewen Li, Yongfeng Lao, Rui Yan, et al.
Gene (2024) Vol. 936, pp. 149125-149125
Closed Access | Times Cited: 1
RNA methylations in hepatic fibrosis, a gradually emerging new treatment strategy
Chenglong Cheng, Yajie Wu, Xin Wang, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Genetic variants in the 6p21.3 region influence hepatitis B virus clearance and chronic hepatitis B risk in the Han Chinese population
Jiancheng Huang, Mingkuan Su, Fanhui Kong, et al.
Liver Research (2024) Vol. 8, Iss. 1, pp. 54-60
Open Access
Page 1

Scroll to top